acute liver dysfunction associated with interferon-beta-1a (avonex®) use in a young female patient with relapsing-remitting multiple sclerosis (rrms)

نویسندگان

علیرضا رضایی آشتیانی

ali reza rezaei ashtiani department of neurology, vali-e-asr. medical center,arak medical university, arak, iran بابک زمانی

babak zamani department of neurology,rasol-e-akram medical center, tehran, iran محمد روحانی

mohammad rohani department of neurology,rasol-e-akram medical center, tehran, iran

چکیده

background: it has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (rrms) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. we report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (avonex®) intramuscular injections in a young female patient with relapsing-remitting multiple sclerosis. case: the patient was 19 year-old female with clinically proved rrms, treated with interferon-beta-1a (avonex®) 30 µg weekly by intramuscular injections for two years. she was referred with clinical symptoms of liver dysfunction including abdominal peri-umbilical and right upper quadrant pain, anorexia and malaise, that constipation, dark urine and icterus. laboratory studies corroborated acute hepatitis state without any viral, autoimmune or drug-related causes. patient's status improved after two weeks of conservative therapy and withholding interferon. billirubin, liver function tests and liver enzyme values returned to normal. conclusion: interferon-beta compounds could have serious hepatic complications, and patients using interferon-beta-1a should regularly monitor their liver function.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Acute Liver Dysfunction Associated With Interferon-Beta-1a (Avonex®) Use in A Young Female Patient with Relapsing-Remitting Multiple Sclerosis (RRMS)

Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...

متن کامل

The use of interferon beta in relapsing-remitting multiple sclerosis.

The use of interferon beta-1a to treat multiple sclerosis in a child of 7 years of age is discussed. To date, there is only one other published report of the use of interferon beta in a child as young as this. One year after commencing treatment she had shown significant clinical improvement, with a marked reduction in number of relapses. In her second year of treatment she suffered a major rel...

متن کامل

Sexual dysfunction in female patients with relapsing‐remitting multiple sclerosis

INTRODUCTION Sexual dysfunction (SD) is one of the common symptoms of multiple sclerosis (MS) and is often underdiagnosed, especially in women. Relapsing-remitting multiple sclerosis (RRMS) is the most widespread form of the disease, but the data on SD occurrence in this particular group of patients is limited. The aim of the study was to analyze the associations between demographic factors, sy...

متن کامل

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)

Recent research has characterized the anatomical connectivity of the cortico-cerebellar system - a large and important fibre system in the primate brain. Within this system, there are reciprocal projections between the prefrontal cortex and Crus II of the cerebellar cortex, which both play important roles in the acquisition and execution of cognitive skills. Here, we propose that this system al...

متن کامل

The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis

BACKGROUND Spinal cord atrophy occurs early in multiple sclerosis (MS) and impacts disability. The therapeutic effect of interferon beta-1a (IFNβ-1a) on spinal cord atrophy in patients with relapsing-remitting (RR) MS has not been explored. METHODS We retrospectively identified 16 consecutive patients receiving weekly intramuscular IFNβ-1a for 2 years [baseline age (mean ± SD) 47.7 ± 7.5 year...

متن کامل

Emerging methods for evaluating the effectiveness of intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis.

Newer outcome-based assessment methods have been developed that complement and improve upon the ability of historical clinical and magnetic resonance imaging (MRI) outcome measures to measure multiple sclerosis (MS) disease activity, patient functionality, treatment efficacy, and the risk of MS disease progression. These newer MS outcome assessments include instruments to evaluate cognitive fun...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
iranian journal of toxicology

جلد ۱، شماره ۳، صفحات ۸-۸

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023